Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old at the time of informed consent~2. Ability to provide written informed consent and HIPAA authorization~3. Solid organ malignancy with documented bone metastasis by imaging~4. Adequate liver function (serum total bilirubin \<= 3 and AST/ALT \<= 3 times the upper normal limit)~5. Adequate renal function (serum creatinine \<= 2mg/dL)~6. Ability to swallow oral tablets~7. Females of childbearing potential must have a negative pregnancy test \<= 28 days prior to registration. All females of childbearing potential who are sexually active, must agree to use a highly reliable method of contraception to prevent pregnancy. These include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).~   NOTE: Females are considered of childbearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal (\> 12 months since last menses).~8. Patients are permitted to participate in other clinical trials while participating in this trial.~9. Patients will receive standard of care systemic treatment for underlying solid malignancy as deemed necessary by treating physician.~Exclusion Criteria:~1. No prior history of bisphosphonate ordenosumab use in the past 12 months~2. No history of SRE within past 3 months~   1. Excruciating bone pain requiring RT~  2. Cord compression~  3. Hypercalcemia \[serum calcium \>10.5\]~  4. Pathologic fracture~3. No history of Paget's disease~4. No history of epilepsy/seizures~5. No history of hypotension (defined as resting systolic blood pressure of \< 110 mm Hg or diastolic blood pressure of \< 70 mm Hg) or orthostasis (defined as drop in systolic blood pressure of \>20 mm Hg or increase in HR of \> 20 from supine to standing position).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guanabenz (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).